- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01091493
Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy (AEPOC-ATB)
Utility of Antibiotic Treatment in Acute Non-purulent Exacerbations of COPD: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy
COPD is one of the most important causes of morbidity and mortality and supposes a sanitary problem in Europe and USA. Patients with COPD usually have 1-2 episodes of acute exacerbation of COPD (AECOPD) per year, being these the principal causes of of hospitalizations, respiratory problems and medical visits. After an episode of AECOPD, the majority of patients develop a transitory (or permanent) worsening in their quality of life and 50% of them will require a new hospitalization. Globally, a 75%& of the exacerbations might be associated with a respiratory tract infection, and among them, 50% might be related to bacteria and in 45% an evidence of viral infection could be documented. Even though the antibiotic treatment might not be useful for a majority of patients with AECOPD, is generalized its use(almost an 85% in some series) in hospitalized patients. The non-controlled use of antibiotics in AECOPD results in a very expensive disease and raises the rate of resistance of bacteria. The available literature have shown that there's a relation between exacerbations and infections, based on sputum samples.
In summary, is well known that at least a 50% of the episodes of AECOPD might be associated with pathogenic bacteria in the lower respiratory tract. Prescription of antibiotics is wide and generalized in hospitalized patients. Clinical trials have shown correlation between AECOPD with sputum purulence (which correlates with presence of bacteria), however they've not included NON-purulent AECOPD, even though they're a significative group of patients hospitalized by this cause too. It's necessary to evaluate the efficacy nor the security of antibiotic treatment in this group of patients in a well designed trial.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Barcelona, Spania, 08006
- Hospital Clínica Platón
-
-
Aragon
-
Zaragoza, Aragon, Spania, 50009
- Hospital Miquel Servet
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08036
- Fundacio Clinic Per la Recerca Biomèdica - Hospital Clinic de Barcelona
-
-
Comunitat Valenciana
-
Valencia, Comunitat Valenciana, Spania, 46009
- Fundació La Fe- Hospital La Fe
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- COPD diagnosis according to GOLD guidelines
- Hospitalization for any acute exacerbation of chronic obstructive pulmonary disease
- Failure of outpatient treatment
- Increasing of dyspnea in the last days
- Comorbidity that causes detriment of respiratory function
Exclusion Criteria:
- Life expectancy of less than 6 months
- Mechanical Ventilation
- Cardiovascular condition that causes exacerbation
- Immunosuppression
- Pulmonary infiltrates that suggest pneumonia
- Antibiotic treatment in the last month
- Pregnancy
- ECG with a large QT segment
- Hypokalemia
- Hepatic failure or renal failure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Non-Antibiotic
Patients will not receive antibiotics, although the study is double-blind.
|
|
Aktiv komparator: Antibiotic
Patients will receive in a masked way, moxifloxacin.
|
Moxifloxacin 400 mg administered once a day for 5 days
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Efficacy of treatment WITHOUT antibiotics in non-purulent exacerbations of COPD
Tidsramme: Six months
|
Six months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Efficacy/Safety in treatment on re-hospitalizations at six months.
Tidsramme: Six monts
|
Six monts
|
|
In-hospital stay (days)
Tidsramme: Six months
|
Six months
|
|
All cause mortality
Tidsramme: One and Six months
|
One and Six months
|
|
Quality of Life (QoL) measured by the Saint George Respiratory Questionnaire
Tidsramme: Hospitalization day 1 and six months
|
This item will be measured by the application of the Saint George Respiratory Questionnaire (SGRQ)
|
Hospitalization day 1 and six months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nestor Soler, MD,PhD, Hospital Clinic of Barcelona
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959-67. doi: 10.1164/ajrccm.154.4.8887592. Erratum In: Am J Respir Crit Care Med 1997 Jan;155(1):386.
- Murray CJ, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon JA, Michaud CM, Walker N, Vos T. Global burden of disease 2005: call for collaborators. Lancet. 2007 Jul 14;370(9582):109-110. doi: 10.1016/S0140-6736(07)61064-2. No abstract available.
- Snow V, Lascher S, Mottur-Pilson C; Joint Expert Panel on COPD of the American College of Chest Physicians and the American College of Physicians-Amercian Society of Internal Medicine. The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1. Chest. 2001 Apr;119(4):1185-9. doi: 10.1378/chest.119.4.1185. No abstract available.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AEPOC-ATB
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Moxifloxacin
-
Hoffmann-La RocheFullførtFriske FrivilligeForente stater
-
AiCuris Anti-infective Cures AGFullført
-
GlaxoSmithKlineFullførtInfluensa, menneskeForente stater
-
University of California, San FranciscoRekrutteringAntibiotikaresistens | Øyeoverflatemikrobiom | Gut ResistomeForente stater
-
Universidade Federal de PernambucoFullførtGrå stær | Endoftalmitt | Macula ødemBrasil
-
Heidelberg UniversityBayerFullført
-
CardioKine Inc.Biogen; Cardiokine Biopharma, LLCFullført
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; SAMI Pharmaceutical...FullførtFriske individer | BioekvivalensstudiePakistan
-
Peking University Third HospitalUkjent
-
WockhardtFullførtQT/QTc-intervall hos friske frivilligeForente stater